India to Cambodia: Amlodipine Export Trade Route

To import Amlodipine formulations into Cambodia, the following approvals and registrations are mandatory:

1. Product Registration: All pharmaceutical products must be registered with the MoH before importation. The registration process involves submitting a comprehensive dossier detailing the product's technical specifications, including quality, safety, and efficacy data.

2. Dossier Format: The required dossier format aligns with the ASEAN Common Technical Dossier (ACTD), which standardizes the documentation for drug registration across ASEAN member states.

3. Timelines for Approval: The MoH aims to notify applicants of its decision within 21 working days from the date of receiving a complete and correct application. (wipo.int)

4. Product Registration Fees: Specific fees associated with product registration are determined by the MoH and may vary based on the product category and complexity of the evaluation process.

5. GMP Inspection Requirements: Manufacturing facilities producing Amlodipine formulations intended for the Cambodian market must comply with Good Manufacturing Practice (GMP) standards. The MoH may require GMP certification from the exporting country's regulatory authority or conduct its own inspections to ensure compliance.

Indian exporters of Amlodipine formulations must meet the following GMP certifications and standards to supply products to Cambodia:

1. GMP Certification: Manufacturers must hold GMP certification recognized by the MoH. This certification should demonstrate adherence to internationally accepted manufacturing standards.

2. Approved Facilities: The MoH maintains a list of approved manufacturing facilities. Indian exporters should ensure their facilities are included in this list to facilitate the importation process.

3. Recent Inspections and Regulatory Actions: The MoH conducts periodic inspections of foreign manufacturing facilities to verify compliance with GMP standards. Any non-compliance identified during these inspections can result in regulatory actions, including suspension or revocation of product registration.

In the past 18 months, several regulatory changes and policy shifts have impacted Indian pharmaceutical exports to Cambodia:

1. Digitalization of Registration Process: In 2019, the MoH launched the Cambodia Pharmaceutical Online Registration System (CamPORS), a digital platform designed to streamline the registration of pharmaceutical products. This system has been continuously updated to enhance efficiency and transparency in the registration process.

2. Strengthened Enforcement Against Unregistered Products: The MoH has intensified efforts to prevent the importation and distribution of unregistered pharmaceutical products. Distributors found circumventing registration requirements face stringent penalties, including fines and revocation of licenses.

3. ASEAN Harmonization of GMP Standards: As of June 2025, ASEAN member states, including Cambodia, have been working towards harmonizing GMP inspection standards to facilitate mutual recognition and streamline the approval process for pharmaceutical products within the region.

These developments underscore Cambodia's commitment to ensuring the quality, safety, and efficacy of pharmaceutical products entering its market, thereby impacting the regulatory landscape for Indian exporters.

As of 2024-2025, Cambodia's market for Amlodipine formulations is expanding, driven by a rising prevalence of hypertension and cardiovascular diseases. The country's healthcare expenditure has been increasing, reflecting a commitment to improving medical infrastructure and access to essential medicines. An aging population further contributes to the demand for antihypertensive medications like Amlodipine. While Cambodia imports a significant portion of its pharmaceutical products, including Amlodipine formulations, domestic manufacturing capabilities are developing but remain limited.

Cambodia imposes a 0% import duty on pharmaceutical products classified under HS Code 30, which encompasses Amlodipine formulations. Additionally, a flat 10% Value Added Tax (VAT) is applied to all imports. Cambodia is a member of the ASEAN Free Trade Area (AFTA), which facilitates reduced tariff rates among member countries. However, specific preferential rates or exemptions for pharmaceutical imports from India under AFTA are not detailed in the available data. There are no reported anti-dumping duties affecting the import of Amlodipine formulations into Cambodia.

India is a primary supplier of Amlodipine formulations to Cambodia, with exports totaling $11.5 million USD across 537 shipments from 83 manufacturers/exporters. This trade route represents 0.1% of India's total Amlodipine formulation exports, valued at $11,497.3 million USD. The top Indian exporters include FORAY LIFE CARE PRIVATE LIMITED ($2.1M), THE MADRAS PHARMACEUTICAL ($1.9M), and TORRENT PHARMACEUTICALS LTD ($1.7M). Major Cambodian buyers are TELPHA INC ($2.9M), K.S PHARMACO LTD ($2.0M), and MAYBANK CAMBODIA PLC ($0.7M). While India dominates the supply of Amlodipine formulations to Cambodia, other countries also contribute to the market. Specific data on the market shares of these countries and comparative pricing information are not provided in the available sources.

India has solidified its position as a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic drugs and meeting 40% of the United States' generic medicine demand as of February 2025. This extensive manufacturing capability is supported by a vast network of facilities adhering to stringent international quality standards. By 2024, India surpassed the United States in the number of FDA-registered generic manufacturing sites, boasting 752 FDA-approved and 2,050 WHO-GMP-certified plants.

The country's cost-effective production processes, combined with economies of scale, enable the manufacturing of high-quality finished dosage forms, including tablets, capsules, and syrups, at competitive prices. This efficiency is particularly advantageous for the production of formulations containing Amlodipine, a widely prescribed antihypertensive medication. The presence of numerous WHO-GMP and FDA-approved facilities ensures that Indian manufacturers can meet the regulatory requirements of diverse international markets, including Cambodia.

When evaluating the sourcing of Amlodipine formulations, India offers a compelling balance of cost and quality compared to other major producers such as China and the European Union. In Q1 2025, the price of Amlodipine Besylate in the United States was $76,440 per metric ton, while in China, it was $72,411 per metric ton, and in Germany, it stood at $75,369 per metric ton. These figures indicate that Indian manufacturers can offer competitive pricing for finished dosage forms containing Amlodipine, benefiting from lower production costs and established supply chains.

In terms of quality, Indian pharmaceutical companies have consistently adhered to international standards, with a significant number of FDA and WHO-GMP-certified facilities. This compliance ensures that Amlodipine formulations produced in India meet the stringent regulatory requirements of importing countries, including Cambodia. While European manufacturers are often associated with high-quality branded generics, their products typically come at a higher cost. Chinese manufacturers, on the other hand, may offer lower prices but have faced challenges related to regulatory compliance and quality perception in certain markets.

For Cambodian buyers, sourcing Amlodipine formulations from India presents a strategic advantage, offering a combination of cost-effectiveness, assured quality, and regulatory compliance.

The India-Cambodia supply chain for Amlodipine formulations has demonstrated reliability, supported by India's robust manufacturing capacity and infrastructure. Indian pharmaceutical companies have been proactive in expanding their production capabilities to meet global demand. For instance, in December 2025, Sun Pharma announced a $332 million investment in a new formulations manufacturing facility in Madhya Pradesh, aiming to enhance production capacity and support global pharmaceutical needs.

Packaging and logistics capabilities in India are well-developed, ensuring that finished dosage forms, including Amlodipine tablets and capsules, are delivered efficiently to international markets. While there have been isolated instances of regulatory scrutiny, such as FDA compliance issues at specific facilities, leading manufacturers have taken corrective actions to address these concerns and maintain supply chain integrity.

Overall, the capacity and reliability of Indian manufacturers in producing and supplying Amlodipine formulations remain strong, with ongoing investments further bolstering this position.

For Cambodian buyers seeking to source Amlodipine formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amlodipine formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts and storage capabilities. Indian manufacturers typically offer flexible MOQs, but clear communication is essential to meet both parties' requirements.

• Payment Terms: Standard payment terms in the India-Cambodia pharmaceutical trade often include letters of credit (LC) or advance payments. Establishing mutually agreeable terms will facilitate smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities, verification of regulatory certifications (such as WHO-GMP and FDA approvals), and assessment of quality control systems.

• Regulatory Compliance: Ensure that the selected suppliers comply with Cambodia's pharmaceutical import regulations and that their products are registered with the Cambodian Ministry of Health.

By implementing these recommendations, Cambodian buyers can establish a reliable and cost-effective supply chain for Amlodipine formulations sourced from India.

By meticulously following these guidelines, Cambodian pharmaceutical companies can ensure the selection of reputable Indian Amlodipine suppliers, thereby safeguarding product quality and patient safety.